Hyperion DeFi (NASDAQ:HYPD) Research Coverage Started at Chardan Capital

Chardan Capital began coverage on shares of Hyperion DeFi (NASDAQ:HYPD) in a research report released on Wednesday, Marketbeat.com reports. The firm issued a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald began coverage on Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperion DeFi in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.58.

Hyperion DeFi Price Performance

HYPD opened at $3.84 on Wednesday. The firm has a market capitalization of $31.37 million, a PE ratio of -0.95 and a beta of 2.80. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.25 and a quick ratio of 2.25. The business’s 50-day moving average is $4.95 and its two-hundred day moving average is $7.54. Hyperion DeFi has a 1 year low of $0.85 and a 1 year high of $17.99.

Hyperion DeFi (NASDAQ:HYPD) last released its quarterly earnings results on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. The business had revenue of $0.36 million for the quarter. Research analysts anticipate that Hyperion DeFi will post -41.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Happy David Walters acquired 61,930 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were acquired at an average price of $3.02 per share, with a total value of $187,028.60. Following the purchase, the director directly owned 111,930 shares of the company’s stock, valued at $338,028.60. This trade represents a 123.86% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Ellen R. Strahlman bought 19,702 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average price of $3.14 per share, with a total value of $61,864.28. Following the completion of the purchase, the director owned 95,150 shares in the company, valued at approximately $298,771. This trade represents a 26.11% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 130,374 shares of company stock worth $398,043. Corporate insiders own 10.86% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.